CSIMarket
 


Candel Therapeutics Inc   (CADL)
Other Ticker:  
 

Candel Therapeutics Inc 's Working Capital Ratio

CADL's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




CADL Working Capital Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Change 23.86 % 21.01 % - - -
Y / Y Current Assets Change -13.06 % 257.51 % - - -
Working Capital Ratio MRQ 14.52 16.06 18.97 15.84 20.68
Overall Ranking # 378 # 0 # 0 # 0 # 388
Seq. Current Liabilities Change 0.15 % 7.83 % -5.95 % 21.95 % -2.16 %
Seq. Current Assets Change -9.45 % -8.7 % 12.6 % -6.6 % 272.35 %



Working Capital Ratio third quarter 2022 Comment
Due to increase in Current Liabilities in the third quarter 2022, Working Capital Ratio fell to 14.52 below Candel Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 31 other companies have achieved higher Working Capital Ratio than Candel Therapeutics Inc in third quarter 2022. While Working Capital Ratio total ranking has deteriorated compare to the prior quarter from 0 to 378.

Explain Working Capital Ratio
Where is CADL most successful ?
Working Capital Ratio CADL on the trailing twelve month basis
Working Capital Ratio third quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 32
Healthcare Sector # 137
Overall Market # 378


Working Capital Ratio Statistics
High Average Low
20.68 15.25 5.44
(Sep 30 2021)   (Jun 30 2021)




Financial Statements
Candel Therapeutics Inc 's Current Liabilities $ 5 Millions Visit CADL's Balance sheet
Candel Therapeutics Inc 's Current Assets $ 79 Millions Visit CADL's Balance sheet
Source of CADL's Sales Visit CADL's Sales by Geography


Cumulative Candel Therapeutics Inc 's Working Capital Ratio

CADL's Working Capital Ratio for the trailling 12 Months

CADL Working Capital Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities TTM Growth 23.86 % 21.01 % - - -
Y / Y Current Assets TTM Growth -13.06 % 257.51 % - - -
Working Capital Ratio TTM 16.3 17.73 15.34 14.05 12.98
Total Ranking TTM # 223 # 279 # 342 # 398 #
Seq. Current Liabilities TTM Growth 0.15 % 7.83 % -5.95 % 21.95 % -2.16 %
Seq. Current Assets TTM Growth -9.45 % -8.7 % 12.6 % -6.6 % 272.35 %


TTM Working Capital Ratio Comment
On the trailing twelve months basis Due to rise in Current Liabilities in the III. Quarter to $5.45 millions, average cumulative Working Capital Ratio decreased to 16.3 below the Candel Therapeutics Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 32 other companies have achieved higher Working Capital Ratio than Candel Therapeutics Inc . While Working Capital Ratio overall ranking has improved so far to 215, from total ranking in previous quarter at 87.

Explain Working Capital Ratio
Where is CADL most successful ?
Working Capital Ratio CADL on the trailing twelve month basis

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 33
Healthcare Sector # 130
Within the Market # 223


TTM Working Capital Ratio Statistics
High Average Low
17 15.47 14.54
(Jun 30 2022)   (Dec 31 2021)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2022, within Biotechnology & Pharmaceuticals Industry Working Capital RatioSep 30 2022 MRQ Current AssetsSep 30 2022 MRQ Current Liabilities
Hillevax Inc   34.77 $ 300.154  Millions$ 8.633  Millions
Singular Genomics Systems Inc   33.76 $ 286.114  Millions$ 8.475  Millions
Seer Inc   33.08 $ 450.471  Millions$ 13.616  Millions
Acumen Pharmaceuticals Inc   30.63 $ 202.560  Millions$ 6.613  Millions
Alpha Pro Tech Ltd   27.43 $ 52.509  Millions$ 1.914  Millions
Astrotech Corp  27.20 $ 51.353  Millions$ 1.888  Millions
Protara Therapeutics Inc   26.59 $ 98.667  Millions$ 3.711  Millions
Arca Biopharma Inc   23.00 $ 44.550  Millions$ 1.937  Millions
Athira Pharma Inc   22.31 $ 228.972  Millions$ 10.264  Millions
Rewalk Robotics Ltd   21.83 $ 78.895  Millions$ 3.614  Millions
Talaris Therapeutics Inc   21.61 $ 198.127  Millions$ 9.168  Millions
Celldex Therapeutics inc   20.54 $ 334.599  Millions$ 16.287  Millions
Quince Therapeutics Inc   19.87 $ 98.276  Millions$ 4.945  Millions
Vor Biopharma Inc   19.43 $ 142.729  Millions$ 7.345  Millions
Fusion Pharmaceuticals Inc   18.02 $ 215.846  Millions$ 11.981  Millions
Icosavax Inc   17.55 $ 228.732  Millions$ 13.033  Millions
Organovo Holdings Inc   17.54 $ 24.357  Millions$ 1.389  Millions
4d Molecular Therapeutics Inc   17.14 $ 232.478  Millions$ 13.564  Millions
Tarsus Pharmaceuticals Inc   16.40 $ 234.078  Millions$ 14.273  Millions
Vaxcyte Inc   16.35 $ 369.759  Millions$ 22.614  Millions
Replimune Group Inc   16.12 $ 379.390  Millions$ 23.537  Millions
Cardiff Oncology inc   15.82 $ 119.755  Millions$ 7.571  Millions
Anavex Life Sciences Corp   15.63 $ 152.705  Millions$ 9.770  Millions
Kymera Therapeutics Inc   15.57 $ 494.022  Millions$ 31.729  Millions
Relay Therapeutics Inc   15.22 $ 1,087.297  Millions$ 71.427  Millions
Candel Therapeutics Inc   14.52 $ 79.070  Millions$ 5.446  Millions
Entera Bio Ltd   14.28 $ 15.190  Millions$ 1.064  Millions
Krystal Biotech Inc   14.18 $ 397.578  Millions$ 28.032  Millions
Tracon Pharmaceuticals inc   14.05 $ 18.020  Millions$ 1.283  Millions
Monte Rosa Therapeutics Inc   13.55 $ 295.235  Millions$ 21.790  Millions

Date modified: 2022-11-13T01:57:22+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

MICS's Profile

Stock Price

MICS's Financials

Business Description

Fundamentals

Charts & Quotes

MICS's News

Suppliers

MICS's Competitors

Customers & Markets

Economic Indicators

MICS's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071